Noteworthy Price Action: Is Selling Stock Like Intra-Cellular Therapies Inc After Such Decline Winning Strategy?

Noteworthy Price Action: Is Selling Stock Like Intra Cellular Therapies Inc After Such Decline Winning Strategy?

The stock of Intra-Cellular Therapies Inc (NASDAQ:ITCI) is a huge mover today! About 539,967 shares traded hands. Intra-Cellular Therapies Inc (NASDAQ:ITCI) has declined 60.83% since April 14, 2016 and is downtrending. It has underperformed by 65.51% the S&P500.
The move comes after 9 months negative chart setup for the $566.09 million company. It was reported on Nov, 16 by Barchart.com. We have $12.87 PT which if reached, will make NASDAQ:ITCI worth $28.30 million less.

Intra-Cellular Therapies Inc (NASDAQ:ITCI) Ratings Coverage

Out of 8 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 6 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 75% are positive. Intra-Cellular Therapies has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock of Intra-Cellular Therapies Inc (NASDAQ:ITCI) has “Overweight” rating given on Thursday, June 2 by Piper Jaffray. The company was maintained on Thursday, September 17 by Guggenheim. JMP Securities downgraded Intra-Cellular Therapies Inc (NASDAQ:ITCI) on Thursday, September 29 to “Market Perform” rating. The firm earned “Outperform” rating on Friday, November 6 by RBC Capital Markets. The stock of Intra-Cellular Therapies Inc (NASDAQ:ITCI) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The stock has “Sell” rating given by Zacks on Friday, August 7. The firm has “Neutral” rating given on Thursday, September 29 by SunTrust.

According to Zacks Investment Research, “Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.”

Insitutional Activity: The institutional sentiment increased to 1.71 in Q2 2016. Its up 0.25, from 1.46 in 2016Q1. The ratio improved, as 17 funds sold all Intra-Cellular Therapies Inc shares owned while 28 reduced positions. 23 funds bought stakes while 54 increased positions. They now own 30.01 million shares or 2.84% more from 29.18 million shares in 2016Q1.
Ecor1 Capital Llc last reported 3.75% of its portfolio in the stock. Clough Cap Ptnrs L P holds 225,650 shares or 0.47% of its portfolio. Bb Biotech Ag has 1.07% invested in the company for 700,000 shares. Axa reported 113,065 shares or 0.02% of all its holdings. The New York-based Tower Ltd Llc (Trc) has invested 0% in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Nationwide Fund Advsr has 0% invested in the company for 22,497 shares. Driehaus Mngmt has invested 0.13% of its portfolio in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Marshall Wace Llp has 9,820 shares for 0% of their US portfolio. Springbok Mgmt Ltd Liability Co accumulated 0.04% or 6,569 shares. Sarissa Cap Management L P last reported 675,000 shares in the company. Citigroup holds 17,098 shares or 0% of its portfolio. Sabby Mngmt Limited Com, a New Jersey-based fund reported 71,943 shares. Bnp Paribas Arbitrage Sa reported 1,329 shares or 0% of all its holdings. Orbimed Limited Company has 0.36% invested in the company for 885,400 shares. Blackrock Grp Limited last reported 485,620 shares in the company.

More recent Intra-Cellular Therapies Inc (NASDAQ:ITCI) news were published by: Fool.com which released: “Why Intra-Cellular Therapies Inc. Is Crashing Today” on September 29, 2016. Also Fool.com published the news titled: “Why Intra-Cellular Therapies Inc. Stock Rocketed 206% Higher In 2015” on January 14, 2016. Fool.com‘s news article titled: “Why Intra-Cellular Therapies Inc Stock Jump 21.4% in April” with publication date: May 07, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment